Login to Your Account

Diamyd's Shares Tumble on Phase II Gene Therapy Miss

By Cormac Sheridan
Staff Writer

Wednesday, August 8, 2012

Shares in Diamyd Medical AB dropped 30 percent Tuesday on news that its gene therapy treatment for cancer pain missed the primary endpoint in a Phase II placebo-controlled trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription